Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.52 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.42 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17902991 | 1.00 | CTSS (0.52) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL12283739 | 1.00 | CTSS (0.52) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL17581833 | 1.00 | CTSS (0.52) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL14012280 | 1.00 | CTSS (0.52) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL23998665 | 0.97 | CTSS (0.51) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL23106074 | 0.92 | CTSK (0.50) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL29593613 | 0.91 | CTSK (0.53) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL25459969 | 0.90 | CTSK (0.48) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL17209941 | 0.90 | CTSK (0.48) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL28342732 | 0.90 | CTSK (0.48) | CTSSCTSKMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3972649-B1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2026-03-05 | — | — | US | disclosed |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2026-01-29 | — | — | US | disclosed |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-12-25 | — | — | US | disclosed |
| EP-4659809-A2 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-20250276074-A1 | BRM AND BRG1 TARGETING ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | PRELUDE THERAPEUTICS INCORPORATED | 2025-09-04 | — | — | US | disclosed |
| EP-3538539-B1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMA (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-4525925-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | Novartis AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| EP-4525926-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | Novartis AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| US-9669106-B2 | Conjugate of monomethyl auristatin F and trastuzumab and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2017-06-06 | — | — | US | disclosed |
| WO-2017072196-A1 | COMPOSITION FOR THE TREATMENT OF IGF-1R EXPRESSING CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-05-04 | — | — | WO | disclosed |
| US-20170112943-A1 | CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-04-27 | — | — | US | disclosed |
| US-20170043032-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-02-16 | — | — | US | disclosed |
| US-20170043031-A1 | IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-02-16 | — | — | US | disclosed |
| US-20170029490-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | ZYMEWORKS INC. (CA) | 2017-02-02 | — | — | US | disclosed |
| EP-3086815-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | Zymeworks Inc. (CA) | 2016-11-02 | — | — | EP | disclosed |
| WO-2016041082-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CDRD Ventures, Inc. (CA) | 2016-03-24 | — | — | WO | disclosed |
| US-20160075735-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2016-03-17 | — | — | US | disclosed |
| WO-2015095953-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2015-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075735-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, PLK1, BOD1L1 | CTSS 834/4885CTSK 1063/4885MEN1 959/4885 |
| US-20170043032-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | KRTCAP2, DDOST, DAD1 | CTSS 2393/4885CTSK 1720/4885MEN1 1555/4885 |
| US-20170112943-A1 | CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER | AURKC, AURKA, EGFR | CTSS 2585/4885CTSK 2068/4885MEN1 427/4885 |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | EPHA2, EPHA1, EPHB1 | CTSS 4451/4885CTSK 4316/4885MEN1 4139/4885 |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | BID, BCL2, MCL1 | CTSS 2817/4885CTSK 3327/4885MEN1 1082/4885 |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | MET, BCL3, BCL9 | CTSS 3241/4885CTSK 2251/4885MEN1 569/4885 |
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | FCGR2A, FCGR3B, BCL3 | CTSS 977/4885CTSK 2216/4885MEN1 4097/4885 |
| US-20170043031-A1 | IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | IGF1R, IGFBP1, IGFBP5 | CTSS 3959/4885CTSK 3396/4885MEN1 285/4885 |
| US-20250276074-A1 | BRM AND BRG1 TARGETING ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | CRBN, RBX1, SMARCE1 | CTSS 3893/4885CTSK 3253/4885MEN1 1360/4885 |
| US-20170029490-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | MPST, TPST2, SULT1A1 | CTSS 877/4885CTSK 2901/4885MEN1 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.